CCR5 and atherosclerosis: An antagonist of CCR5, maraviroc, was administered in human immunodeficiency virus (HIV) patients for 24 weeks and several markers of atherosclerosis were measured as follows: brachial flow-mediated dilation (bFD), carotid-femoral pulse wave velocity (cFPWV) and carotid intima-media thickness (cIMT).